ArticleJournal of epidemiology and community health2004
Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases.
Article in Journal of epidemiology and community health, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis.BMC medicine · 2014 · on this mapPooled it
- Peripheral neuropathy in HIV: prevalence and risk factors.AIDS (London, England) · 2011Trial
- Inflammatory and neurotoxic risk of atorvastatin in diabetic peripheral neuropathy: TNF-centered evidence integrating network toxicology, scRNA-Seq, and cell validation.Frontiers in chemistry · 2026Article
- Statin therapy and neuropathy in type 1 diabetes: A cross-sectional study.Diabetes, obesity & metabolism · 2025Article
- Lipid-lowering drugs (statins) and peripheral neuropathy.Electronic physician · 2018Article
- Statins and polyneuropathy revisited: case-control study in Denmark, 1999-2013.British journal of clinical pharmacology · 2017Article
- [Polyneuropathy in the elderly].Zeitschrift fur Gerontologie und Geriatrie · 2017Review
- Review
- Effectiveness of oral bisphosphonates for primary prevention of osteoporotic fractures: evidence from the AIFA-BEST observational study.European journal of clinical pharmacology · 2014Observational
- Absence of clinical relationship between oxidized low density lipoproteins and diabetic peripheral neuropathy: a case control study.Lipids in health and disease · 2014Article
- A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.Drugs · 2013Review
- Selected statins produce rapid spinal motor neuron loss in vitro.BMC musculoskeletal disorders · 2012Article
- Aloe barbadensis Mill. formulation restores lipid profile to normal in a letrozole-induced polycystic ovarian syndrome rat model.Pharmacognosy research · 2012Article
- My legs are getting old: sinvastatin-induced polyneuropathy.BMJ case reports · 2011Article
- Residual microvascular risk in diabetes: unmet needs and future directions.Nature reviews. Endocrinology · 2010Review
- Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study.Diabetologia · 2008Article
- Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2008Review
- Advances in understanding drug-induced neuropathies.Drug safety · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STUDY
objectiveAlthough lipid lowering drugs are effective in preventing morbidity and mortality from cardiovascular events, the extent of their adverse effects is not clear. This study explored the association between prescription of lipid lowering drugs and the risk of peripheral neuropathy.
designA population based case-control study was carried out by linkage of several automated databases.
settingResident population of a northern Italian Province aged 40 years or more.
participantsCases were patients discharged for peripheral neuropathy in 1998-1999. For each case up to 20 controls were randomly selected among those eligible. Altogether 2040 case patients and 36 041 controls were included in the study. Exposure ascertainment: Prescription drug database was used to assess exposure to lipid lowering drugs at any time in the one year period preceding the index date. ANALYSIS: Conditional logistic regression model for matched data was used to estimate the risk of peripheral neuropathy associated with exposure to statins, fibrates, and other lipid lowering drugs. MAIN
resultsWeak but significant effects of lipid lowering drugs as a whole (matched odds ratio: 1.27; 95% confidence intervals: 1.05 to 1.55), statins (1.19; 1.00 to 1.40), and fibrates (1.49; 1.03 to 2.17) were observed. Significant linear trends towards increased risk at increased exposure to both statins and fibrates were observed.
conclusionsThe use of both statins and fibrates was associated with the risk of peripheral neuropathy. The primary purpose of this exploratory study is signal generation. This requires further investigations to evaluate the causal role of lipid lowering drugs on the onset of peripheral neuropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.